The knee hyaluronic acid injections market can grow up to 4,156.1 million USD from 2,410.2 million USD between 2026 and 2036, at a compound annual growth rate of 5.6%. This will be driven primarily by continued demand for minimally invasive osteoarthritis treatments, escalating demand for alternatives to opioid pain relief, and increased adoption of viscosupplementation therapies as a standard procedure prior to knee replace surgeries. The single, three, and five injection formats are being used based on factors such as disease severity, physician preference, and patient compliance, which are supporting steady volumes, especially in developed and developing markets, according to FMI’s study.
FMI focuses on the development of treatment personalization, as well as the diversification of settings, as pivotal structural developments affecting the overall market. Though the condition of knee osteoarthritis dominates the use of painkillers in this market, additional uses in ligament injury recovery and pain management post-arthroscopy are significant drivers of overall consumption. Regardless, hospitals and ambulatory surgery centers continue to lead overall painkiller use, with rheumatology clinics supplementing this with repeat use of painkillers. There is also additional relevance in terms of pharmacies, as this reflects the fundamental shift in the delivery of musculoskeletal care.
Recent developments among leading manufacturers underscore this evolution. Major players are focusing on next-generation formulations, including cross-linked and combination hyaluronic acid products designed to improve durability and clinical response. Anika Therapeutics, Inc. has commercially launched CINGAL® in Canada, its third-generation viscosupplement. “CINGAL represents a significant major advancement among viscosupplements, and we're excited that Canadians with knee pain can now access a new and more effective treatment option," said Charles H. Sherwood, Ph.D., President and Chief Executive Officer. "We are pleased to expand our partnership with Pendopharm to accelerate demand for CINGAL by leveraging their established physician networks and distribution channels, which led to the commercial successes of ORTHOVISC and MONOVISC in Canada.”
The trend in the future will be such that the portfolio strategies will constantly be shifting towards long-term management of osteoarthritis rather than short-term management, owing to investments in differentiated injection regimens, clinical evidence, and physician educational initiatives, which are helping suppliers move up the musculoskeletal care value chain, ultimately resulting in brand loyalty, repeat business, and growth throughout the forecast period to 2036, particularly to augment the management of the escalating disease burden associated with orthopedics without increasing the extent of the surgeries.
Future Market Insights projects the knee hyaluronic acid injections market to expand at a CAGR of 5.6% from 2026 to 2036, increasing from USD 2,410.2 million in 2026 to USD 4,156.1 million by 2036. Demand is being sustained by continued use of viscosupplementation in outpatient osteoarthritis care, where symptom control and delayed escalation to surgery remain prioritized.
FMI Research Approach: Historical market sizing, injection procedure volumes, dosing-schedule mix, outpatient orthopedic throughput, and country adoption indicators were used to model demand through 2036.
Future Market Insights states that, the product selection is increasingly being shaped by dosing convenience and clinic workflow efficiency, supporting a larger shift toward multi-injection regimens alongside steady uptake of single-injection formats. Incremental differentiation is being pursued through formulation positioning and next-generation combinations, although adoption remains selectively physician-led.
FMI Research Approach: Adoption curves were assessed across injection schedules and formulation types, aligned to real-world outpatient utilization and specialist prescribing patterns.
The United States holds the largest share in the global knee hyaluronic acid injections market, supported by high osteoarthritis patient volumes, broad orthopedic access, and established outpatient administration infrastructure, alongside repeat treatment utilization within structured care pathways.
FMI Research Approach: Country-level inputs included osteoarthritis burden, outpatient injection volumes, specialist density, and coverage-linked utilization patterns.
The global knee hyaluronic acid injections market is projected to reach USD 4,156.1 million by 2036.
FMI Research Approach: Market size was calculated by modeling demand across the dominant indication and dosing schedule mix using weighted utilization factors.
As per Future Market Insights, conservative knee osteoarthritis management pathways are supporting continued use of hyaluronic acid injections, particularly where clinic-administered pain relief and functional improvement are pursued before surgical intervention. Demand is also being reinforced by repeat dosing cycles and outpatient follow-up structures.
FMI Research Approach: Treatment pathway intensity, outpatient delivery expansion, and repeat utilization dynamics were incorporated into forecasting models.
| Metric | Details |
|---|---|
| Industry Size (2026) | USD 2,410.2 million |
| Industry Value (2036) | USD 4,156.1 million |
| CAGR (2026-2036) | 5.6% |
Source: Future Market Insights (FMI) analysis, based on proprietary forecasting model and primary research
As pre FMI, the demand for knee hyaluronic acid injections growing as knee osteoarthritis care remains anchored in staged, non-surgical management across large outpatient populations. Utilization is being supported by repeatable clinic-based administration and physician preference for viscosupplementation as an intermediate option when oral therapies and physiotherapy provide insufficient relief. Demand concentration is being observed in osteoarthritis (92.0% share) and in three-injection regimens (47.8% share), where symptom-control continuity and established practice patterns remain monetizable. End-user demand is being led by ambulatory surgical centers (32.1%) and orthopedic clinics (25.5%), reflecting the outpatient shift in musculoskeletal care delivery. As conservative treatment pathways persist and outpatient volumes rise, viscosupplement injections are being retained as recurring therapy choices within orthopedic practice.
The knee hyaluronic acid injections market is segmented by product, indication, and end user. By product, the market includes single injection knee hyaluronic acid injections, three injection knee hyaluronic acid injections, five injection knee hyaluronic acid injections, and next generation (steroid combination). Based on indication, demand is categorized into knee osteoarthritis, ligament injury, and post-arthroscopy. By end user, the market is segmented into hospitals, ambulatory surgical centers, orthopedic clinics, retail pharmacies, and online sales channels. This segmentation reflects differences in treatment protocols, care-setting preferences, and patient access pathways.
The three-injection regimens of hyaluronic acid injection products have the highest market share because of the appropriate balance between the efficacy and practicality of the product. This shows the dominance of the three-injection products, which have an estimated market share of 47.8%, with the total demand for the products, as stated earlier. It has the largest market share because it can be effectively used to treat osteoarthritis, considering the need to continuously relieve the symptoms.
From a clinical standpoint, three-injection products have been the preferred choice of orthopedic surgeons for the treatment of patients presenting with moderate disease progression, which necessitates the need for a prolonged effect of the treatment that three-injection products can offer over other single-injection products. These products have worked well within the clinical environment of outpatient treatment schemes, which offers further advantages. The clinical familiarity of these products within key markets is another positive point for the three-injection treatment schemes, which has helped these products to hold the reference standard within the treatment protocols of viscosupplementation.
The major indication is knee osteoarthritis, which accounts for 92.0% of the overall percentage of the use of hyaluronic acid injection. It is the major clinical indication in the overall management process, especially for those patients using the injectable treatment as a form of symptom management or as a method for delaying the replacement of the diseased joints.
Such an approach has placed hyaluronic acid injections at a midway position between conservative treatment failure and surgery, making it an integral part of any treatment algorithm for osteoarthritis. The demand for this treatment option is further fueled by the number of cycles that may be involved for chronic patients and the desire for less invasive approaches that avoid systemic pain relief. Based on the current treatment scope, the only demand driver for this treatment option is knee osteoarthritis.
The role of regulatory oversight and clinical guideline recommendations can also be recognized while considering the use and application of hyaluronic acid injections in knee osteoarthritis therapy and management. Patient selection, disease severity stratification, and documentation of outcomes can also be identified as major factors, which are influencing the use and application of hyaluronic acid injections according to standardized treatment protocols. Besides, the importance of safety profiling can also be recognized while influencing the demand for well-characterized formulations with documented clinical use history.
The prescription practices of healthcare providers are adapting the use of injections in a manner that is aligned and dictated by evidence-based pathways. As value-based care systems grow in stature and application, treatment decisions are being made based on considerations of symptom relief as well as improvements in functionality and reduced need for future interventions. It is in this area that hyaluronic acid injections are gaining value.
This new dynamic of outpatient and ambulatory care for orthopedic conditions is changing what this market for knee injections of hyaluronic acid looks like. With demands rising for more ambulatory and outpatient orthopedic care, efficiency and cost-effectiveness are the hallmarks of ambulatory surgical centers and orthopedic offices. Formats of injections being less frequent and providing longer relief are key considerations.
Ambulatory adoption is also driven by the patient’s choice to avoid care environments such as the hospital setting, as well as easier scheduling. As the trend within healthcare continues toward reduced inpatient orthopedic exposure, viscosupplementation is being incorporated in streamlined outpatient treatment options, which is driving continued growth in demand within the clinic or ambulatory setting.
There has been an increase in the emphasis in product innovation for knee hyaluronic acid injections, such that the formulation optimizations and combinations are becoming the focus in this area. There is an increase in the development of state-of-the-art products, which combine hyaluronic acid with corticosteroids and adjunctive agents, so that early pain relief can be maximized while the benefits of joint lubrication can be retained for longer.
The aim of these developments is to differentiate products within a rather mature therapeutic category, while recognizing differences in drug response, or lack thereof. As clinicians increasingly search for drugs that are capable of providing rapid results with long-term effects, formulation innovation is emerging as a major factor in determining product competition in the future.
According to Future Market Insights, the United States (CAGR ~3.8%), China (~8.9%), India (~7.8%), Japan (~8.2%), the United Kingdom (~5.5%), and Germany (~4.0%) as the six core demand drivers for knee hyaluronic acid injections globally. The USA is expected to remain at the top by virtue of established practices in viscosupplementation in orthopedic and pain management clinics, driven by high volumes of osteoarthritis patients. China and India are the key contributors in the growth segment, given the rise in osteoarthritis along with increased access to orthopedic clinics and outpatient services, where osteoarthritis treatment is seen as a step before major surgical consequences. The growth in Japan is further driven by patient demography and treatment preference towards symptom management while allowing ambulatory activities in daily life. Germany is driven by a consistent volume, driven by conservative practices in orthopedic clinics, including strict adherence to guidelines and emphasis on product quality and clinical evidence. The growth in the UK is being driven by measured practices in orthopedic clinics, where osteoarthritis treatment is an important component in symptom management. The opinion of FMI is that these countries represent high chronic disease, along with an increase in outpatient orthopedic clinics, creating resilient demand throughout 2036.
| Country | CAGR (2026-2036) |
|---|---|
| China | 8.9% |
| Japan | 8.2% |
| India | 7.8% |
| United Kingdom | 5.5% |
| Germany | 4.0% |
| United States | 3.8% |
Source: Future Market Insights (FMI) analysis, based on proprietary forecasting model and primary research
The U.S. market for knee injections of hyaluronic acid is due to record growth at a CAGR of 3.8%, primarily through the routine and established usage within orthopedic practices and discomfort management. The requirement is being fueled by the extensive number of osteoarthritis patients seeking improvements and discomfort alleviation prior to surgical procedures. Future Market Insights points out that such injections are being recognized as an alternative choice, particularly in situations where conservative methods have failed and alleviation of movement is a priority, particularly in the working as well as elderly patient populations. They are being supported by the typical outpatient delivery systems and consistent familiarity, particularly among physicians in the country.
As per Future Market Insights, knee hyaluronic injections will see an estimate rise at an 8.9% CAGR during the forecast period. The report has stated that this is due to the rise in access to orthopedic services and a rise in the number of people being diagnosed with degenerative problems of the knee. Additionally, the service of hyaluronic injections is gaining greater strength due to the rise of outpatient departments of hospitals that are providing space to the service of orthopaedics. As per the report, acceptance of the service of viscosupplement is broadening as symptom management is the key priority, and maintenance of ability to perform activities is being prioritized, especially within urban areas.
India as a high-growth market, which is poised to register a CAGR of approximately 7.8%, driven by increasing osteoarthritis burden and growing access to orthopedic interventions through private hospitals and specialty clinics. Utilization is being further strengthened due to the adoption of minimally invasive symptom management options that can delay or reduce immediate dependence on surgical options. The growth is supported by expanding ambulatory care settings where injections can be carried out efficiently followed by structured physiotherapy and pain-management support. Increased patient awareness and higher care-seeking behavior in urban and semi-urban areas are going to keep demand structurally supported throughout the forecast period.
Germany’s knee hyaluronic acid injections market to grow at a 4.0% CAGR, supported by evidence-led adoption patterns rather than volume-led expansion. Demand is being shaped by conservative clinical decision-making, where product performance expectations and patient selection discipline are being prioritized. FMI notes that utilization is being sustained within orthopedic and rheumatology settings where non-surgical symptom relief is being pursued under structured care pathways. Consistent preference for high-quality, well-characterized products is expected to keep market growth stable, with demand being driven by clinical appropriateness and long-term mobility outcomes.
Japan’s knee hyaluronic acid injections market is expected to expand at an 8.2% CAGR, shaped by an aging population and sustained focus on maintaining daily function and mobility. Demand is being reinforced by the high prevalence of degenerative joint conditions and a strong preference for non-surgical symptom control in older patient cohorts. FMI analysts emphasize that viscosupplementation is being utilized as part of longitudinal disease management, where repeat treatment cycles can be planned within routine outpatient care. Adoption is expected to remain structurally supported as mobility preservation continues to be treated as a key quality-of-life priority.
The future growth prospects for the knee hyaluronic acid injection industry in the UK stand at a 5.5% CAGR as the industry exhibits tempered growth in the use of such injections in the process of managing the various conditions of orthopedic pathways, where the management and preservation of condition symptoms continue to be a priority consideration. This indicates a continued boost in demand as the industry utilizes the injections as a tool for managing symptoms in patients undertaking non-surgical pathways for their cases. Analysts at the Future Market Insights organization project this growth to be tempered due to service capacity and pathway selection.
As per FMI, the competition within the market for knee hyaluronic acid injections is being driven increasingly by factors of differentiation, convenience of dosage administration, and congruence with advancing standards of osteoarthritis management, rather than the commodity-driven concept of volume. The emphasis of manufacturers is on the enhancement of optimal molecular weight distribution, types of cross-linking, as well as injection methods to ensure the longevity of pain relief benefits.
Another defining strategic move in the market is the shift in simplified dosing protocols, which is receiving significant weightage in the form of Single Injection Knee Hyaluronic Acid Injections and Three Injection Knee Hyaluronic Acid Injections. Companies such as Sanofi S.A. and Zimmer Biomet are heavily investing in these to cater to the increased need amongst physicians to avoid multiple clinic visits and finish the treatment quickly, especially in the aging population. Five Injection Knee Hyaluronic Acid Injections, however, remain in consideration in certain situations that require the need for elongated dosing.
FMI also pointed that the rise of innovations in the Next Generation (Steroid Combination) category of products, wherein companies are reportedly investigating combination approaches to improve short-term symptom relief while preserving the benefit of the viscoelastic profile of Hyaluronic Acid. The strategic expansions across hospital systems, Ambulatory Surgery Clinics, Ortho Clinics, coupled with the aforementioned retail pharmacy/online sales reach, are contributing to shaping the competitive landscape of the market.
Recent Developments:
The knee hyaluronic acid injections market is considered an industry involved in the manufacture and use of hyaluronic acid-based intra-articular injectables for managing pathology relating to the knee joint. In other words, it relates to the use and manufacture of injectables targeting the knee joint to enhance the viscosity and elasticity of the synovial fluid and therefore alleviate pain as a result of various pathology affecting the knee joint. The market size is therefore set in terms of millions during the forecast period from 2026 to 2036.
The market includes hyaluronic acid injection products administered through single injection knee hyaluronic acid injections, three injection knee hyaluronic acid injections, five injection knee hyaluronic acid injections, and next generation (steroid combination) formulations. These products are used across multiple Indications, including knee osteoarthritis, ligament injury, and post-arthroscopy care, and end users are hospitals, ambulatory surgical centers, orthopedic clinics, retail pharmacies, and online sales channels.
The market excludes oral hyaluronic acid supplements, topical joint treatments, platelet-rich plasma therapies, stem cell injections, corticosteroid-only injections, and surgical interventions such as knee replacement procedures. Also excluded are hyaluronic acid products indicated for non-knee joints, cosmetic dermatology applications, veterinary use, or experimental research settings.
| Items | Values |
|---|---|
| Quantitative Units (2026) | USD 2,410.2 Million |
| Product | Single Injection Knee Hyaluronic Acid Injections, Three Injection Knee Hyaluronic Acid Injections, Five Injection Knee Hyaluronic Acid Injections, Next Generation (Steroid Combination) |
| Indication | Knee Osteoarthritis, Ligament Injury, Post-Arthroscopy |
| End User | Hospitals, Ambulatory Surgical Centers, Orthopedic Clinics, Retail Pharmacies, Online Sales |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Countries Covered | USA, Germany, UK, China, Japan, India, Brazil, and 40+ countries |
| Key Companies Profiled | Sanofi S.A., Bioventus LLC, Ferring B.V., Zimmer Biomet, Seikagaku Corporation, Fidia Farmaceutici S.p.A., Anika Therapeutics, Inc. |
| Additional Attributes | Revenue analysis by product type and indication, assessment of dosing preference trends, evaluation of distribution channel expansion, competitive positioning based on formulation innovation and clinical adoption |
What is the current global market size for knee hyaluronic acid injections?
The global knee hyaluronic acid injections market is valued at USD 2,410.2 million in 2026, reflecting sustained utilization of viscosupplementation in osteoarthritis management across hospital and outpatient settings.
What is the projected CAGR for the market over the next 10 years?
The market is projected to grow at a 5.6% CAGR from 2026 to 2036, supported by rising osteoarthritis prevalence, aging populations, and preference for non-surgical pain management options.
Which regions are experiencing the fastest expansion?
China, Japan, and India are experiencing the fastest expansion, with growth rates above 7%, driven by increasing diagnosis rates, expanding orthopedic care access, and rising acceptance of injection-based therapies.
What are the primary market drivers?
Growth is being driven by increasing knee osteoarthritis incidence, demand for pain relief delaying joint replacement, growing adoption of single- and three-injection regimens, and wider availability across ambulatory care settings.
Who are the leading manufacturers in the market?
Sanofi, Bioventus, Zimmer Biomet, and Ferring are among the leading manufacturers, differentiated through branded viscosupplement portfolios, clinical evidence generation, and strong orthopedic channel presence.
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
Knee Hyaluronic Acid Injections Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
